| Item Type | Name |
|
Academic Article
|
Skin cancer is among the most costly of all cancers to treat for the Medicare population.
|
|
Academic Article
|
Nonmelanoma skin cancer: an episode of care management approach.
|
|
Academic Article
|
Frequency of seborrheic keratosis biopsies in the United States: a benchmark of skin lesion care quality and cost effectiveness.
|
|
Academic Article
|
The cost of psoriasis therapies: considerations for therapy selection.
|
|
Academic Article
|
The impact of biologics on the quality of life of psoriasis patients and the economics of psoriasis care.
|
|
Academic Article
|
The burden of atopic dermatitis: impact on the patient, family, and society.
|
|
Academic Article
|
Involving the patient: impact of inflammatory skin disease and patient-focused care.
|
|
Academic Article
|
Quality of life in patients with psoriasis.
|
|
Academic Article
|
Frequency and cost of actinic keratosis treatment.
|
|
Academic Article
|
Medication adherence and health care costs associated with biologics in Medicaid-enrolled patients with psoriasis.
|
|
Academic Article
|
Do utilization management controls for phototherapy increase the prescription of biologics?
|
|
Academic Article
|
Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period.
|
|
Academic Article
|
The pharmacoeconomics of acne treatment: where are we heading?
|
|
Academic Article
|
Surgical decision making for basal-cell carcinoma of the face.
|
|
Academic Article
|
Equating topical treatment of severe psoriasis to keeping money in a mattress.
|
|
Academic Article
|
Paradoxical effects of cost reduction measures in managed care systems for treatment of severe psoriasis.
|
|
Academic Article
|
Pharmacoeconomic considerations in treating actinic keratosis.
|
|
Academic Article
|
Prior authorization for topical psoriasis treatments: is it cost-beneficial for managed care?
|
|
Academic Article
|
Cost-effectiveness of a hydroquinone/tretinoin/fluocinolone acetonide cream combination in treating melasma in the United States.
|
|
Academic Article
|
Review of home phototherapy.
|
|
Academic Article
|
Medication use and associated health care outcomes and costs for patients with psoriasis in the United States.
|
|
Academic Article
|
A pharmacoeconomic analysis of severe psoriasis therapy: a review of treatment choices and cost efficiency.
|
|
Academic Article
|
Characteristics of office-based physician visits for cutaneous fungal infections. an analysis of 1990 to 1994 National Ambulatory Medical Care Survey Data.
|
|
Academic Article
|
Efficacy, safety, and cost of office-based surgery: a multidisciplinary perspective.
|
|
Academic Article
|
The economic burden of skin disease in the United States.
|
|
Academic Article
|
Strategy to manage the treatment of severe psoriasis: considerations of efficacy, safety and cost.
|
|
Academic Article
|
The importance of skin disease as assessed by "willingness-to-pay".
|
|
Academic Article
|
Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction.
|
|
Academic Article
|
Medication and health care service utilization related to depressive symptoms in older adults with psoriasis.
|
|
Academic Article
|
The prevalence of psoriasis in African Americans: results from a population-based study.
|
|
Academic Article
|
Medication-related factors affecting health care outcomes and costs for patients with psoriasis in the United States.
|
|
Academic Article
|
Members of the national psoriasis foundation: more extensive disease and better informed about treatment options.
|
|
Academic Article
|
Treatments for mild-to-moderate recalcitrant plaque psoriasis: expected clinical and economic outcomes for first-line and second-line care.
|
|
Academic Article
|
Incidence rates, costs, severity, and work-related factors of occupational dermatitis: a workers' compensation analysis of Oregon, 1990-1997.
|
|
Academic Article
|
Where has Goeckerman treatment gone?
|
|
Academic Article
|
The rise of the generic drug market and its implications for dermatology.
|
|
Academic Article
|
Cost-effectiveness of moderate-to-severe psoriasis treatment.
|
|
Academic Article
|
Home ultraviolet B phototherapy: a cost-effective option for severe psoriasis.
|
|
Academic Article
|
The cost-effectiveness and cost of treatment failures associated with systemic psoriasis therapies.
|
|
Academic Article
|
Predictors of healthcare outcomes and costs related to medication use in patients with acne in the United States.
|
|
Academic Article
|
New treatments for psoriasis: which biologic is best?
|
|
Academic Article
|
Would elimination of copayments for phototherapy decrease the cost of treating psoriasis with systemic biologics? A cost analysis.
|
|
Academic Article
|
Treatment patterns and cost of nonmelanoma skin cancer management.
|
|
Academic Article
|
Treating skin disease: self-management behaviors of Latino farmworkers.
|
|
Academic Article
|
Does cost-effectiveness play a role in clinical trials?
|
|
Academic Article
|
Written action plans: potential for improving outcomes in children with atopic dermatitis.
|
|
Academic Article
|
The cost-effectiveness of rosacea treatments.
|
|
Academic Article
|
Utilization pattern of etanercept and its cost implications in moderate to severe psoriasis in a managed care population.
|
|
Academic Article
|
Prescription refills and healthcare costs associated with topical metronidazole in Medicaid enrolled patients with rosacea.
|
|
Academic Article
|
A Medicare cost comparison of minor cutaneous procedures by surgical setting.
|
|
Academic Article
|
Management and costs of severe psoriasis: the role of new biologics.
|
|
Academic Article
|
Prescribing patterns for topical retinoids: analyses of 15 years of data from the national ambulatory medical care survey.
|
|
Academic Article
|
A review of home phototherapy for psoriasis.
|
|
Academic Article
|
Health reform in North Carolina: market hazard, moral imperative: why we need health reform.
|
|
Academic Article
|
Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States.
|
|
Academic Article
|
The economic impact of non-melanoma skin cancer: a review.
|
|
Academic Article
|
Cost per responder analysis of ustekinumab and etanercept for moderate to severe plaque psoriasis.
|
|
Academic Article
|
Medication choice and associated health care outcomes and costs for patients with acne and acne-related conditions in the United States.
|
|
Concept
|
Cost Sharing
|
|
Concept
|
Health Care Costs
|
|
Concept
|
Cost-Benefit Analysis
|
|
Concept
|
Cost Savings
|
|
Concept
|
Costs and Cost Analysis
|
|
Concept
|
Drug Costs
|
|
Concept
|
Hospital Costs
|
|
Concept
|
Cost of Illness
|
|
Concept
|
Cost Control
|
|
Academic Article
|
Medication adherence, healthcare costs and utilization associated with acne drugs in Medicaid enrollees with acne vulgaris.
|
|
Academic Article
|
Cost effectiveness of biologic therapies for plaque psoriasis.
|
|
Academic Article
|
Explicit and implicit copayments for phototherapy: examining the cost of commuting.
|
|
Academic Article
|
Using a single product (calcipotriene/betamethasone topical suspension) vs multiple products to manage body and scalp psoriasis: comparisons in resource utilization and costs.
|
|
Academic Article
|
Disease burden and treatment adherence in psoriasis patients.
|
|
Academic Article
|
Treatment sequencing after failure of the first biologic in cost-effectiveness models of psoriasis: a systematic review of published models and clinical practice guidelines.
|
|
Academic Article
|
The economic burden of psoriasis: a systematic literature review.
|
|
Academic Article
|
The cost of biologics for psoriasis is increasing.
|
|
Academic Article
|
Patterns of medication utilization and costs associated with the use of etanercept, adalimumab, and ustekinumab in the management of moderate-to-severe psoriasis.
|
|
Academic Article
|
Economic and comorbidity burden among moderate-to-severe psoriasis patients with comorbid psoriatic arthritis.
|
|
Academic Article
|
Economic and Comorbidity Burden Among Patients with Moderate-to-Severe Psoriasis.
|
|
Academic Article
|
The cost-effectiveness of ustekinumab for moderate-to-severe psoriasis.
|
|
Academic Article
|
Costs of Common Psoriasis Medications, 2010-2014.
|
|
Academic Article
|
The cost of applying to dermatology residency.
|
|
Academic Article
|
Cost-Effectiveness of Ivermectin 1% Cream in Adults with Papulopustular Rosacea in the United States.
|
|
Academic Article
|
Commentary on Cost of Actinic Keratoses and Skin Cancers.
|
|
Academic Article
|
First-Line Fixed-Combination Psoriasis Treatment Is Associated With Lower Healthcare Costs.
|
|
Academic Article
|
Pharmacoeconomic Considerations in Treating Actinic Keratosis: An Update.
|
|
Academic Article
|
Assessing the overall benefit of a medication: cumulative benefit of secukinumab over time in patients with moderate-to-severe plaque psoriasis.
|
|
Academic Article
|
Variation in cash price of the generic medications most prescribed by dermatologists in pharmacies across the United States.
|
|
Grant
|
Hawthorne Conference on Office-Based Surgery
|
|
Academic Article
|
Cost of diagnosing psoriasis and rosacea for dermatologists versus primary care physicians.
|
|
Academic Article
|
Economic burden of comorbidities in psoriasis patients in the United States: results from a retrospective U.S. database.
|
|
Academic Article
|
Budget impact model in moderate-to-severe psoriasis vulgaris assessing effects of calcipotriene and betamethasone dipropionate foam on per-patient standard of care costs.
|
|
Academic Article
|
Healthcare costs in psoriasis and psoriasis sub-groups over time following psoriasis diagnosis.
|
|
Academic Article
|
Rethinking the costs of psoriasis management.
|
|
Academic Article
|
Cost-effectiveness analysis of using dermatologists versus pediatricians to treat mild to moderate acne.
|
|
Academic Article
|
Higher Psoriasis Skin Clearance Is Associated with Lower Annual Indirect Costs in the United States: A Post Hoc Analysis from the CLEAR Study.
|
|
Academic Article
|
Major Comorbidities of Atopic Dermatitis: Beyond Allergic Disorders.
|
|
Academic Article
|
Adherence and resource use among psoriasis patients treated with biologics.
|
|
Academic Article
|
Comparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment in the United States.
|
|
Academic Article
|
Public Perception of Ethical Issues in Dermatology: Evidenced by New York Times Commenters.
|
|
Academic Article
|
Patient Costs Associated with Rosacea.
|
|
Academic Article
|
Effect of Prior Biologic Use on Cost-Effectiveness of Brodalumab vs. Ustekinumab for Treatment of Moderate-to-Severe Psoriasis in the United States.
|
|
Academic Article
|
Biosimilars for Immune-Mediated Chronic Diseases in Primary Care: What a Practicing Physician Needs to Know.
|
|
Academic Article
|
Cost Per Additional Responder Associated With Ixekizumab and Etanercept in the Treatment of Moderate-to-Severe Psoriasis.
|
|
Academic Article
|
Economic Impact of Above-Label Dosing with Etanercept, Adalimumab, or Ustekinumab in Patients with Psoriasis.
|
|
Academic Article
|
Real-world US healthcare costs of psoriasis for biologic-naive patients initiating apremilast or biologics.
|
|
Academic Article
|
Pharmacy costs of systemic medications for hidradenitis suppurativa in the United States.
|
|
Academic Article
|
Treatment patterns and costs among biologic-naive patients initiating apremilast or biologics for psoriatic arthritis.
|
|
Academic Article
|
Tracking the price of existing biologics when drugs enter the market.
|
|
Academic Article
|
Health Care Utilization and Cost Associated with Biologic Treatment Patterns Among Patients with Moderate to Severe Psoriasis: Analyses from a Large U.S. Claims Database.
|
|
Academic Article
|
The Challenge of Variable Costs in Decisions Based on Cost-Effectiveness Evidence: A Case Study for Brodalumab.
|
|
Academic Article
|
Real-world treatment patterns and healthcare costs of biologics and apremilast among patients with moderate-to-severe plaque psoriasis by metabolic condition status.
|
|
Academic Article
|
The Cash Pharmacy Model May Effectively Lower Prescription Drug Prices.
|
|
Academic Article
|
Psoriasis causes as much disability as other major medical diseases.
|
|
Academic Article
|
Comparative cost-effectiveness of tildrakizumab and other commonly used treatments for moderate-to-severe psoriasis.
|
|
Academic Article
|
Utilization of an Online Cash-Pay Pharmacy for Topical 5-Fluorouracil Prescriptions in Older Patients.
|
|
Academic Article
|
Safe Step Act: does it undermine step therapy?
|
|
Academic Article
|
Cost-effectiveness of tildrakizumab for the treatment of moderate-to-severe psoriasis in the United States.
|
|
Academic Article
|
Real-world biologic and apremilast treatment patterns and healthcare costs in moderate-to-severe plaque psoriasis.
|